Physician profile
Robert Carter
NPI 1063480788
$1,560.45
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,076 · 2020: $470 · 2022: $14.60.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $259.36 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $233.69 | 2019-2020 | |
| Novo Nordisk INC | $212.93 | 2019-2020 | |
| Pfizer INC. | $185.97 | 2019-2020 | |
| Glaxosmithkline, LLC. | $94.11 | 2019-2020 | |
| Lilly USA, LLC | $73.73 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $71.18 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $58.72 | 2019-2020 | |
| Kaleo, INC. | $56.25 | 2020 | |
| Melinta Therapeutics, LLC | $46.51 | 2019 | |
| Novartis Pharmaceuticals Corporation | $46.48 | 2019-2020 | |
| Amarin Pharma, INC. | $42.43 | 2020 | |
| Shire North American Group INC | $39.58 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $34.71 | 2019 | |
| Amgen INC. | $33.04 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $18.22 | 2019 | |
| Astellas Pharma US INC | $15.55 | 2019 | |
| Boston Scientific Corporation | $14.60 | 2022 | |
| Ironshore Pharmaceuticals INC. | $11.76 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.63 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.